Latest news with #Novotech
Forbes
a day ago
- Business
- Forbes
What Nearly Blowing My Promotion Taught Me About Leadership
Toyna Chin is the Global Director of Marketing at Novotech, a global biotech CRO. A few years ago, I stepped into a new role through an internal promotion. I'd been with the company for a while, understood the people and had a strong pulse on the business. Naturally, I thought I was ready to hit the ground running. Spoiler alert: I wasn't. Almost immediately, I found myself creating tension. Not because I had bad ideas, but because I was too eager to act without fully understanding my new reality. I later picked up What Got You Here Won't Get You There by Marshall Goldsmith, and the title alone felt like it was written for me. It helped me reflect on why my instincts (which had served me well until that point) were suddenly working against me. Here's what I wish I had done differently and what I eventually figured out the hard way. In my prior role, I was valued for being proactive, decisive and solution-focused. When I moved up, I leaned on those same traits—but now they were landing differently. Instead of being seen as helpful, I came off as pushy. I was unintentionally steamrolling people who had more context than I did. I remember diving into a team meeting and immediately suggesting changes to a process I thought was outdated. What I didn't realize was that this 'outdated' process had been carefully developed to meet very real constraints I hadn't yet uncovered. That was my first big leadership lesson: Leading from the middle is very different from leading from above. Execution and influence are not the same thing. My job was no longer to drive every solution but to enable the team to solve the right problems. One trap I fell into was assuming that my tenure gave me all the insight I needed. I'd been involved in cross-functional projects, sat in on leadership meetings and even contributed to some strategic planning. But I didn't realize how much nuance I was missing until I started asking more questions. Eventually, I slowed down and started meeting with key stakeholders—not to tell them my vision, but to ask for theirs. I asked questions like: • 'What's working well that you'd want to protect?' • 'Where do you think I can be most helpful?' • 'What do you want me to understand before I try to change anything?' Those conversations gave me insight that no dashboard or report ever could. I realized I had a few puzzle pieces—but not the whole picture. I came into the role with good intentions, but my early attempts to make improvements were met with hesitation. It wasn't until I stepped back and focused on building trust that things began to shift. I started by owning what I didn't know. I became more transparent about my learning curve and started showing more appreciation for the team's existing efforts. I stopped assuming and started listening with patience. And something powerful happened: the resistance faded. People became more open, more engaged and, ironically, more receptive to change. They felt respected and included in the process. There was a process I was certain we needed to sunset. In my mind, it was inefficient and outdated. But when I spoke to the team that created it, I heard the backstory. That process wasn't built in a vacuum; it was born from constraints, limited resources and a lot of trial and error. Instead of scrapping it immediately, I invited the team to revisit it with me. We explored what still served us and what we'd outgrown. Together, we built something better. That collaboration turned what could've been seen as a teardown into a shared success. It taught me something critical: Honoring past work isn't about clinging to the old. It's about showing people that their efforts matter—and that progress is something we create together. I had a new title, new responsibilities and formal decision-making power. But the moment I tried to rely on that power alone, I hit walls. Influence, I realized, comes from alignment, not hierarchy. So I brought people into the conversation early. I started socializing ideas instead of announcing them. I gave space for feedback, even when it was hard to hear. Over time, something shifted: the team stopped seeing change as my agenda and started treating it as our direction. Looking Back: Growth Requires A Gear Shift That promotion was a turning point for me not just professionally, but personally. It challenged my assumptions, exposed some blind spots and ultimately reshaped how I lead today. Goldsmith's premise still rings true: The skills that get you promoted won't necessarily make you successful in your new role. Transitioning into leadership requires letting go of old habits, embracing new ones and remembering that people don't follow titles—they follow trust. If you've recently stepped into a new role or have one on the horizon, here's my advice: don't rush to prove yourself. Start by listening, aligning and showing people that you respect the journey they've been on. Because when people trust that you see them, they'll walk with you even when the path changes. Forbes Communications Council is an invitation-only community for executives in successful public relations, media strategy, creative and advertising agencies. Do I qualify?
Business Upturn
5 days ago
- Business
- Business Upturn
Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges
Sydney, Australia: As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory partner has published a new white paper examining the opportunities and challenges shaping this fast-evolving landscape of therapeutic class. This press release features multimedia. View the full release here: LBPs, which harness live microorganisms to restore or modulate human health, are being explored across a growing range of indications, from gastrointestinal and metabolic disorders to CNS and oncology. FDA approvals of Rebyota™ and Vowst™ have validated the category but for most biotech sponsors, the journey remains uncertain. According to Novotech's analysis, over 90% of LBP assets are still in early development stages, and nearly one-third of all trials from 2020 to 2025 have been withdrawn or suspended due to regulatory, manufacturing, or design complexities. Highlights from the report include: A growing pipeline of preclinical and Phase I–II LBP candidates, with notable concentration in Alzheimer's, IBD, diabetes, and NASH. Over 90 industry-sponsored trials launched since 2020, yet 32% have experienced discontinuation. North America and Europe leading in regulatory approvals and manufacturing activity, with rising interest from biotechs in Asia-Pacific. A projected CAGR of 38% for the LBP and microbiome CDMO market through 2030. The global market for LBPs and microbiome contract development and manufacturing organizations (CDMOs) was valued at USD 31.84 million in 2023. With growing investment in players like Vedanta Biosciences and MaaT Pharma, the LBP field is maturing but also becoming more competitive. Success will depend on smart trial design, global regulatory navigation, and efficient feasibility execution. Drawing on deep therapeutic expertise in microbiome-related studies and gastrointestinal, metabolic, and immunologic indications, Novotech supports sponsors from early development through global trial delivery. With operations spanning Asia-Pacific, North America, and Europe, Novotech is uniquely positioned to help biotech and small to mid-size pharma companies translate LBP potential into clinical success. Download the full white paper 'Why Live Biotherapeutics Matter to Emerging Biotech' here. For further information, please visit About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results. For more information or to speak to an expert team member visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Wire
5 days ago
- Business
- Business Wire
Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges
SYDNEY--(BUSINESS WIRE)--As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory partner has published a new white paper examining the opportunities and challenges shaping this fast-evolving landscape of therapeutic class. LBPs, which harness live microorganisms to restore or modulate human health, are being explored across a growing range of indications, from gastrointestinal and metabolic disorders to CNS and oncology. FDA approvals of Rebyota™ and Vowst™ have validated the category but for most biotech sponsors, the journey remains uncertain. According to Novotech's analysis, over 90% of LBP assets are still in early development stages, and nearly one-third of all trials from 2020 to 2025 have been withdrawn or suspended due to regulatory, manufacturing, or design complexities. Highlights from the report include: A growing pipeline of preclinical and Phase I–II LBP candidates, with notable concentration in Alzheimer's, IBD, diabetes, and NASH. Over 90 industry-sponsored trials launched since 2020, yet 32% have experienced discontinuation. North America and Europe leading in regulatory approvals and manufacturing activity, with rising interest from biotechs in Asia-Pacific. A projected CAGR of 38% for the LBP and microbiome CDMO market through 2030. The global market for LBPs and microbiome contract development and manufacturing organizations (CDMOs) was valued at USD 31.84 million in 2023. With growing investment in players like Vedanta Biosciences and MaaT Pharma, the LBP field is maturing but also becoming more competitive. Success will depend on smart trial design, global regulatory navigation, and efficient feasibility execution. Drawing on deep therapeutic expertise in microbiome-related studies and gastrointestinal, metabolic, and immunologic indications, Novotech supports sponsors from early development through global trial delivery. With operations spanning Asia-Pacific, North America, and Europe, Novotech is uniquely positioned to help biotech and small to mid-size pharma companies translate LBP potential into clinical success. Download the full white paper 'Why Live Biotherapeutics Matter to Emerging Biotech' here. For further information, please visit About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results.
News.com.au
12-06-2025
- Business
- News.com.au
‘Over the top' house sells for $18.5m
It was described as capturing 'the romance and timeless beauty of a Mediterranean villa', and the house known as 'Formentera' certainly does that. You won't find too many grand Australian homes with internal finishes quite like this. Even its latest vendors, sources say, considered them a bit 'over the top'. The grand six-bedroom home at 86 Lang Rd, Centennial Park, has just sold for $18.5m after 27 days on the market via Ray White Double Bay's Ashley Bierman and Thomas Popple, in conjunction with Ben Collier and Daniel Acocks at The Agency. But it had been on the market since last September with Collier, initially with hopes of $23m. The result fell at the lower end of its latest $18.5m-$20m guide, with the buyers known to be banker Andrew Cox and his partner, Pru, moving from 22 Attunga St, Woollahra that's listed with Collier. They no doubt factored in a reno for the Lang Rd mansion, to bring it more in line with Australian contemporary tastes. The recent Wentworth Courier House of the Week property, which gets its name from the smallest of the Spanish Balearic Islands, is currently owned by Rob Speedie, Novotech CFO, and Annabelle Mooney, the former JPMorgan managing director. The pair bought the four-storey house in 2021 for $12.5 million from car dealers Paul and Elizabeth Warren, of the Peter Warren Automotives clan. Perhaps it was these previous owners who were behind the 'exquisite hand-painted ceilings, architectural detailing, and a warm Mediterranean palette'. The marble kitchen, with its island bench, Ilve cooker and integrated Sub-Zero fridges, has all the mod cons, but is probably set for a makeover. What would have sold the place, though, was the 854sqm landholding in a prime location on millionaire's row in Centennial Park, with the buyers looking beyond the current design of the 650sq m of internal living space. As Kirsten Craze wrote in her recent feature: 'Outdoors, the landscaped grounds include a European parterre front yard with a pond and manicured hedges, as well as a rear yard with a huge pool, a paved terrace and lawn. 'The first floor is home to a family bathroom plus four bedrooms including the palatial primary and secondary suite, both with large dressing rooms, balconies and deluxe ensuites. 'One more level includes a fifth bedroom or teenager retreat with adjoining sitting room, a walk-in wardrobe and ensuite. Above the double lock up garage and utility room, a convenient one-bedroom au pair or guest apartment comes complete with a kitchen and bathroom, as well as its own private entrance. 'Across from Centennial Park, Formentera is within easy access of Woollahra shops, Oxford St, the Allianz Stadium precinct, Entertainment Quarter, horse riding and the Sporting Club of Sydney.'
Business Upturn
11-06-2025
- Business
- Business Upturn
Novotech Showcased in Global Biotech Series for Innovation in Hepatitis B Research
Sydney, Australia: Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is featured in The Next Frontier, a global branded series presented by the Biotechnology Innovation Organization (BIO) and produced by BBC StoryWorks Commercial Productions. This press release features multimedia. View the full release here: Novotech, a global (CRO) and scientific advisory company, is featured in The Next Frontier, a global branded series presented by BIO and produced by BBC StoryWorks Commercial Productions. The Next Frontier explores how biotechnology is addressing some of the world's most urgent health and sustainability challenges. As part of the series, Novotech highlights its partnership with Tune Therapeutics in advancing a functional cure for Hepatitis B, a chronic disease impacting nearly 300 million people globally. As the global leader in Hepatitis clinical trials, Novotech brings deep therapeutic expertise and global execution capabilities to accelerate development and delivery for sponsors. Filmed in New Zealand with world-leading hepatologist Professor Edward Gane, where an estimated 100,000 people are living with Hepatitis B, the feature highlights Novotech's partnership model for supporting biotech and small to mid-size pharma sponsors. It demonstrates how Novotech accelerates clinical development through access to expert investigators, targeted patient populations, and efficient trial infrastructure across Asia-Pacific, Europe, and North America, while showcasing its global capabilities in infectious disease research and trial delivery. 'Our inclusion in this series reflects Novotech's commitment to supporting innovators with smarter, faster, and more regionally tailored clinical solutions,' said Tom Hickey, Director of Therapeutic Strategy. 'Hepatitis B remains a significant global health challenge, and our teams are proud to have such a long history contributing to meaningful progress in this area.' The series will officially launch at the BIO International Convention in Boston on June 16, 2025, and is now available globally via digital platforms at . About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results. For more information or to speak to an expert team member visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
